natgillin/translations-raw huggingface dataset:
The wing according to claim 9, wherein said at least one structural element is a mast or a spar. 
N) nanesenih uz pomoć najmanje jednog elementa strukture (30), kao što je jarbol ili greda.
Compound according to claim 1, wherein Y is S or SO2. 
Spoj u skladu s patentnim zahtjevom 1, gdje Y je S ili SO».
oxidation of hydroxy compound D or D *, particularly using a Swern oxidation, to create compound E or E *, respectively; 
(b) oksidacija hidroksi spoja D ili D*, naročito pomoću Swern oksidacije, kako bi se dobio spoj E odnosno spoj E*; s Q
The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence at least 80% identical to the non-BC, DE, and FG loop regions of SEQ ID NO: 118, 273, 281, or 331. 
Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što polipeptid sadrži aminokiselinski slijed najmanje 80 %, 85 %, 90 %, 95 %, 98 %, 99 % ili 100 % istovjetan područjima koja nisu petlje BC, DE, te FG u SEQ ID NO: 331, 273, 281 ili 115.
Such a product is commercially available from the Tarkett AB under the trademark TORO EL. 
Takav je proizvod komercijalno dostupan od tvrike Tarkett AB pod zaštitnim znakom TORO EL.
In certain aspects, the buffer is succinate at a final concentration of 1 mM to 10 mM and pH 5.8 to 6.0. 
Formulacija u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je pufer sukcinatni, u konačnoj koncentraciji od 1 mM do 10 mM, uz pH od 5,8 do 6,0.
The volume of water miscible organic solvent necessary to dissolve or suspend the compactin can be easily determined by one of ordinary skill in the art with little or no experimentation. 
Volumen organskog otapala koje se miješa s vodom, potreban za otapanje ili suspenziju kompaktina, može stručnjak ovog područja lako odrediti uz malo, ili bez eksperimentiranja.
Compact fluorescent lamp according to any of the previous claims characterized in that the cap (3) and/or the guide ring (11) are made of visible light transparent material. 
Kompaktna fluorescentna žarulja prema bilo kojem od prethodnih zahtjeva, naznačena time što su poklopac (3) i prsten (11) izrađeni od prozirnog materijala. t>&
The system for relieving high blood sugar factor of diabetes as claimed in claim 2, wherein the total time of the at least one non-energy period is 115, 134, 211, 231, 238, 96, 144 or 36 seconds. 
Sustav za smanjivanje visokog faktora krvnog šećera kod dijabetesa u skladu s patentnim zahtjevom 2, naznačen time što je ukupno trajanje najmanje jednog neenergijskog perioda 115, 134, 211, 231, 238, 96, 144 ili 36 sekundi.
In vitro Example 1. Inhibition of glutathione S-transferase isoenzymes. 
In vitro Primjer 1: Inhibicija izoenzima glutation S-transferaze.
it comprises at least 20% more charged N-glycosidically linked carbohydrate chains of the total carbohydrate units or of at least one particular carbohydrate chain at a particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from ATCC No. 
- sadrži najmanje 20% više nabijenih N-glikozidno vezanih ugljikohidratnih lanaca u ukupnim ugljikohidratnim jedinicama ili u najmanje jednom određenom ugljikohidratnom lancu na određenom mjestu glikoziliranja u molekuli proteina kod molekula proteina u navedenom pripravku s molekulom proteina u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
A fragment of FliD is preferably a fragment of FliD, preferably of full-length FliD, whereby the fragment has an amino acid sequence which is long enough so as to allow a person skilled in the art to identify the fragment to be a fragment of FliD and full-length FliD in particular and to exclude that the fragment is a fragment of a protein or polypeptide different from FliD and full-length FliD in particular. The same considerations and definitions equally apply to a nucleic acid coding for FliD. 
Postupak za otkrivanje H. pylori infekcija kod subjekta, naznačen time da postupak obuhvaća otkrivanje imunološkog odgovora protiv FliD u uzorku subjekta, pri čemu imunološki odgovor sadrži anti-FliD protutijelo, pri čemu postupak obuhvaća reakciju uzorka s FliD ili njegov fragment, gdje fragment ima aminokiselinsku sekvencu koja je dovoljno duga da se identificira fragment koji je fragment FliD 1 da se isključi da je fragment fragment proteina ili polipeptida koji se razlikuje od FliD.
The compound as described in claim 1, wherein the compound is effective to treat pathologies or disorders related to the presence of Propionibacterium acnes. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se upotrebljava u liječenju patoloških pojava ili poremećaja povezanih s prisutnošću bakterije Propionibacterium acnes.
The ultrasound power should, on the one hand, be high enough to create cavitation and, on the other hand, so low that the tooth is not harmed. 
Snaga ultrazvuka, s jedne strane, treba biti dovoljno visoka da kreira šupljinu, a s druge strane treba biti dovoljno visoka da dođe do kavitacije, a da se ne oštete zubi.
The compound or salt for use according to any one of Claims 5, 6, 7 or 8, wherein the use is in simultaneous, separate, or sequential combination with another anti-epileptic drug. 
Spoj, ili sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 5, 6, 7 ili 8, naznačen time što se upotrebljava u istodobnoj, odvojenoj ili uzastopnoj kombinaciji s drugim antiepileptičkim lijekom.
The invention also concerns processes for the manufacture of said quinazoline derivatives, to pharmaceutical compositions containing them and to their use in therapeutic methods, for example in the manufacture of medicaments for use in the prevention or treatment of solid tumour disease in a warm-blooded animal such as man. 
Ovaj izum se isto tako odnosi na postupke za proizvodnju gore spomenutih derivata kinazolina, na farmaceutske smjese koje ih sadržavaju, i na njihovu upotrebu u zdravstvenim postupcima, na primjer u proizvodnji lijekova za upotrebu u prevenciji ili liječenju krutih tumora u toplokrvnoj životinji poput čovjeka.
Use according to any one of claims 1 to 9, wherein the pharmaceutical composition further comprises an additional therapeutic compound, distinct from the population of metallic nanoparticles, intended to treat cancer. Use according to any one of claims 1 to 10, wherein said mammalian cell is a human cell. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu farmaceutski sastav nadalje obuhvaća dodatnu terapijsku tvar namijenjenu za liječenje raka, navedena terapijska tvar je različita od populacije zlatnih nanočestica.
The drug-containing layer excludes polyvinylpyrrolidone,methylcellulose, ethylcellulose and/or hydroxypropylcellulose or contains an amount of less than 2% of polyvinylpyrrolidone,methylcellulose, ethylcellulose and/or hydroxypropylcellulose by weight of the layer; 
Pripravak u skladu sa bilo kojim od prethodnih zahtjeva, naznačen time, da sloj koji sadrži lijek obuhvaća manje od 2% težinski polivinilpirolidona, metilceluloze, etilceluloze i hidroksipropilceluloze.
Process for the iodination of aromatic compounds 
POSTUPAK ZA JODIRANJE AROMATSKIH TVARI
Via the diode bridge 47, capacitor 48 charges and the voltage across its terminals stabilizes once the breakdown voltage of zener 49 is reached. 
Preko diodnog mosta 47, kondenzator 48 se nabija i napon na njegovim stezaljkama se stazbilizira kad se postigne probojni napon zener diode 49.
For the purposes of this specification, Absorbance Ratio of a material is defined as the absorbance of an 0.1% (w/v) solution of solids in water at 280 nm divided by the absorbance of the same solution at 560 nm. 
Za svrhe ove specifikacije, omjer apsorbancije materijala se definira kao apsorbancija 0,1%-tne (mas/v) otopine čvrstih tvari u vodi pri 280 nm, podijeljeno s apsorbancijom iste otopine pri 560 nm.
The solvent was evaporated and purification by chromatography on silica gel eluting with a mixture of dichloromethane/methanol in the proportions 100/0 to 70/30 led to compound in the form of a yellow solid (0.328g). Mp: 232-234°C. 
Otapalo se otpari, a pročišćavanje kromatografijom na silikagelu, uz eluiranje smjesom diklormetan/metanol, u odnosima od 100/0 do 70/30, daje spoj u obliku žute krutine (0,328 g).
The cell according to claim 7, wherein the electrode compartment includes a supply system to supply oxygen to the compartment. 
Odjeljak elektrode sukladno zahtjevu 1 ili 2, naznačen time što ovaj uključuje sustav opskrbe za opskrbu odjeljka kisikom.
As shown in FIG. 10, the juicer element 111 is secured to the bottom of the blender container 106 . 
Kako je prikazano na Slici 10, sokovnik 111 je pričvršćen za dno posude mješalice 106.
As already discussed above, the surface-reacted natural calcium carbonate can be used in combination with a cationic polymeric flocculant as well with an anionic polymeric flocculant, thereby improving process flexibility in water treatment. 
Uporaba površinski-reagiranog prirodnog kalcij karbonata u kombinaciji sa polimernim flokulantom kao što je definirano u jednom od zahtjeva 1 do 15 za pročišćavanje vode.
of less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1%; 
manji od 10%, manji od 5%, manji od 4%, manji od 3%, manji od 2% ili manji od 1%;
A pharmaceutical composition according to claim 10, wherein the further, pharmaceutically active compound has an anti-tumor activity. 
Farmaceutski sastav u skladu s patentnim zahtjevom 10, pri čemu daljnja farmaceutski aktivna tvar ima protutumorsku aktivnost.
The system according to claim 1 comprising a mechanism arranged to couple with an up hole end of the drill string and impart torque to the drill string. 
Sustav (10) sukladno bilo kojem od prethodnih zahtjeva koji sadrži mehanizam koji je prilagođen za sprezanje sa gornjim krajem svrdla za bušenje (14) i za prenošenje obrtnog trenutka na svrdla za bušenje (14).
The pharmaceutical composition for use according to claim 20, wherein the leukemia is selected from acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloproliferative disorder/neoplasm and myelodysplastic syndrome. 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 20, pri čemu je leukemija odabrana između akutne limfocitne leukemije, kronične limfocitne leukemije, kronične mijeloične leukemije, mijeloproliferativnog poremećaja/neoplazme 1 mijelodisplastičnog sindroma.
In another embodiment, the invention relates to compounds of formula I wherein R1 represents cyclobutyl, cyclopentyl or cyclohexyl. 
Spoj u skladu s patentnim zahtjevom 10, naznačen time, da R1 predstavlja ciklobutil, ciklopentil ili cikloheksil.
cutting means for cutting said sheet into napkins; and adhesive applying apparatus according to any one of claims 1 to 6. 
sredstva za rezanje za rezanje navedenog lista materijala u ubruse; i uređaj prema zahtjevu 1 ili zahtjevu 2
The immunoconjugate of claim 8, wherein the immunoconjugate has the formula Ab-(L-MMAE)p, wherein L is a linker and p ranges from 2 to 5, or has the formula Ab-(L-MMAF)p, wherein L is a linker and p ranges from 2 to 5. 
Imunokonjugat prema zahtjevu 8, naznačen time, da imunokonjugat ima formulu Ab-(L-MMAE)p, pri čemu L je poveznica i p je u rasponu od 2 do 5, ili ima formulu Ab-(L-MMAF)p, pri čemu L je poveznica i p je u rasponu od 2 do 5.
4, with at least one of the mutations selected from the group consisting of amino acid Q at position 1 being replaced by N, amino acid S at position 28 being replaced by N, amino acid S at position 31 being replaced by T, amino acid V at position 33 being replaced by L, amino acid D at position 34 being replaced by A, amino acid Y at position 49 being replaced by F, amino acid T at position 53 being replaced by N, amino acid Y at position 55 being replaced by A, amino acid L at position 89 being replaced by Q, and amino acid N at position 93 being replaced by Y. 
4, gdje se najmanje jednu od mutacija bira iz skupine koju čine aminokiselina Q na položaju 1, zamijenjena s N, aminokiselina S na položaju 28, zamijenjena s N, aminokiselina S na položaju 31, zamijenjena s 'T, aminokiselina V na položaju 33, zamijenjena s L, aminokiselina D na položaju 34, zamijenjena s A, aminokiselina Y na položaju 49, zamijenjena s F, aminokiselina T na položaju 53, zamijenjena s N, aminokiselina Y na položaju 55, zamijenjena s A, aminokiselina L na položaju 89, zamijenjena s Q, te aminokiselina N na položaju 93, zamijenjena SY.
and Y4 each independently represents a hydrogen atom, a group selected from group A described below, or a group represented by the following formula (II): wherein 
Y* i Y* svaki nezavisno predstavlja atom vodika, grupu koja je odabrana od grupe A koja je opisana ispod, ili grupu koja je predstavljena sljedećom formulom (II): gdje
introducing the raw material into a processing chamber; heating the raw material with electromagnetic energy in the near field range of at least one non-gas dielectric waveguide by evanescently coupling electromagnetic energy of electromagnetic waves passing through and confined within the at least one waveguide with the material, the electromagnetic energy being sufficient to heat and vaporize the substance, thereby resulting in a treated material wherein a portion of the substance has been extracted from the raw material; and, removing the treated material from the processing chamber. 
Način za ravnomjerno zagrijavanje materijala mikrovalnom energijom, pri čemu način uključuje: osiguravanje sirovine, kao što je jedna ili više vrsta voća, povrća, voćnih sokova, sokova od povrća, prethodno kuhanih žitarica, bakterijskih kultura, cjepiva, enzima, izolata proteina, hidrokoloida, injektabilnih lijekova, farmaceutskih lijekova, antibiotika, antitijela, mesa, ribe, morskih plodova, mlijeka, sireva, izolata proteina surutke, jogurta, voćnih ekstrakata, ekstrakata povrća ili ekstrakata mesa; uvođenja sirovine u procesnu komoru (24); zagrijavanja sirovine mikrovalnom energijom u bliskopoljnom dometu najmanje jednog neplinskog dielektričnog valovoda (42) putem kratkotrajnog povezivanja mikrovalne energije mikrovalova koji prolaze kroz i zadržavaju se unutar najmanje jednog valovoda (42) s materijalom, pri čemu je mikrovalna energija dostatna za zagrijavanje sirovine, što dovodi do zagrijanog materijala; i HR P20181492 T1 uklanjanja zagrijanog materijala iz procesne komore (24).
In one embodiment, the fluorophenyl group is 2-fluorophenyl, 3-fluorophenyl or 4-fluorophenyl. Preferably, R1 is 2-fluorophenyl. 
Tvar iz patentnog zahtjeva 1, pri čemu je R, fluorofenil, a R2 je definiran u patentnom zahtjevu 1, pri čemu je poželjno R, 2-fluorofenil.
A method according to claim 12, comprising bringing sludge to the treatment with said superheated steam in a continuous process, and removing sludge from the treatment with said superheated steam. 
Metoda u skladu s patentnim zahtjevom 12, karakterizirana donošenjem mulja na tretiranje za vrijeme tretiranja superzagrijanom parom u kontinuiranom postupku, i uklanjanje mulja iz postupka tretiranja superzagrijanom parom.
Composition according to claim 5 which is suitable for parenteral administration. 
Pripravak prema patentnom zahtjevu 5, naznačen time da je pogodan za parenteralno davanje.
hydrolyzing said compound of formula N to form a compound of formula Q: wherein: 
hidroliziranja navedenog spoja formule N, tvorbom spoja formule Q:
A method of making a therapeutic cellular composition for delivery to a recipient, comprising the steps of: providing a donor source of hematopoietic stem cells (HSCs); and 
Postupak priprave terapeutskog staničnog pripravka za primjenu na primatelju koji obuhvaća korake: osiguravanje donorskog izvora humanih krvotvornih matičnih stanica (HKMS, engl.
The system of claim 17, wherein the coker (36) is a delayed coker. 
Sustav u skladu s patentnim zahtjevom 17, naznačen time, da je koker (36) produženi (delayed) koker.
The ready-meal package according to claim 1, wherein the main container, the secondary container and the covering means are made of material specifically intended for use in microwaves. 
Paket gotove hrane (1) prema jednom od prethodnih zahtjeva, gdje su glavni spremnik (2), sekundarni spremnik (3) i sredstva za pokrivanje (4) napravljeni od materijala koji je specifično namijenjen za uporabu u mikrovalnoj pećnici.
Thereby is achieved that the dispensing tube is not pressurized and handling thereof is facilitated. 
Time se postiže da cijev za točenje nije izložena pritisku i rukovanje s njom je olakšano.
A cytotoxic T lymphocyte (CTL) according to claim 11 for use in killing target cells in a patient wherein said target cells aberrantly express a polypeptide comprising an amino acid sequence given in claim 1 or 2. 
Citotoksični T-limfocit (CTL) u skladu s patentnim zahtjevom 11 za uporabu u liječenju karcinoma uništavanjem ciljnih stanica u pacijentu, pri čemu ciljne stanice abnormalno predstavljaju peptid u skladu sa SEQ ID br. 2.
10 illustrates the cross-sectional view of the blender container 106 . 
Slika 10 daje poprečni prikaz posude mješalice 106.
Clause 9. The minimally invasive skin treatment device of clause 8, the tool further comprising a sleeve, wherein the cutting blade is at least partially slidably disposed within the sleeve. 
Uređaj za minimalno invazivni tretman kože u skladu s patentnim zahtjevom 8, naznačen time, da alat dodatno obuhvaća naglavak (304), pri čemu je nož za rezanje barem djelomično klizno postavljen unutar naglavka.
The AvPAL variant of claim 4, wherein said pegylation is achieved by reacting the AvPAL variant with NHS-activated polyethylene glycol at a ratio of 3 polyethylene glycol per lysine residue of AvPAL variant. 
AVvPAL varijanta u skladu s patentnim zahtjevom 5, naznačena time, da se može dobiti reakcijom AvPAL varijante s polietilen glikolom aktiviranim NHS-om u omjeru 3 polietilenglikola po ostatku lizina AvPAL varijante.
A method of prophylaxis and/or treatment for radiation dermatitis comprising administering to patient in need thereof the hydrogel of any one of paragraphs 6-10 and/or the lotion of any one of paragraphs 11-19. 
Hidrogel iz bilo kojeg od zahtjeva 1 - 2 i/ili losion iz bilo kojeg od zahtjeva 3 - 6 za korištenje kod profilakse i/ili tretmana radijacijskog dermatitisa.
In another aspect of the present invention, the present invention provides a method of receiving a signal, includes receiving a signal transmitted from a specific radio frequency (RF) channel, demodulating the received signal, parsing a signal frame of the demodulated signal, and obtaining a physical layer pipe (PLP) located in a layer-1 information region of a second pilot signal from the signal frame. 
Postupak primanja emitiranja okvira signala digitalne televizije, DTV, naznačen time, što se sastoji od: primanja (S541, S543) prenošenog signala iz radio frekvencije, RF, kanala; dekodiranja okvira signala od primljenog signala, okvir signal se sastoji od korisnih sadržaja i uvoda, uvod obuhvaća prvi pilot signal koji prethodi drugom pilot signalu, drugi pilot signal uključujuće sloj-1 informacije u čemu vod na fizičkom sloju, PLP, je uključen u korisne sadržaje i drugi pilot signal, i dobivanja ($547) PLP iz okvira signala pomoću sloja-1 informacija.
Primary delusions are defined as arising out-of-the-blue and not being comprehensible in terms of normal mental processes, whereas secondary delusions may be understood as being influenced by the person's background or current situation. 
Primarne iluzije su definirane kao iznenadno-pojavljujuće i neobjašnjive sa stanovišta normalnih mentalnih procesa, dok se sekundrane iluzije mogu tumačiti kao rezultat osobnog utjecaja ili trenutačne situacije.
represents -X-R4a a substituent at the 3-position of the pyrrolidinyl ring; 
predstavlja supstituent -X-R4a na 3-položaju pirolidinil prstena;
The antibody or fragment for use of claim 1, wherein the amount of anti-sclerostin antibody administered is from 1 mg/kg to 3 mg/kg. 
š Antitijelo za uporabu prema zahtjevu 1, naznačeno time, da je količina Anti-sklerostin antitijela koja se primjenjuje od 1 mg/kg do 3 mg/kg.
The process of claim 16, wherein the temperature profile during the curing step c) shows a plateau-like form and wherein said temperature is at least about 72° C. and the curing time is in the range of from about 15 minutes to about 2 hours. 
Postupak prema zahtjevu 16, naznačen time da temperaturni profil u toku koraka stvrdnjavanja pokazuje oblik platoa i gdje je navedena temperatura barem oko 72 "€ i gdje je vrijeme stvrdnjavanja poželjno u rasponu od oko 15 minuta do oko 2 sata.
To achieve higher efficacy and prevent the development of drug resistance, the compounds of the invention may be combined with the following non-exhaustive list of known and marketed antimalarial drugs: artesunate, artemether, di-hydro-artemisinin, mefloquine, chloroquine, sulfadoxine, pyrimethamine, piperaquine, pyronaridine, lumefantrine or atovaquone. 
Farmaceutski sastav prema zahtjevu 3, naznačen time, da druga ljekovita tvar je artesunat, artemeter, dihidroartemisinin, meflokin, klorokin, sulfadoksin, pirimetamin, piperakin, pironaridin, lumefantrin ili atovakuon.
An embodiment of the present invention relates to a 1-thio-D-glucitol compound of the following formula I, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt: 
HR P20110791 TI PATENTNI ZAHTJEVI Spoj 1-tio-D-glucitol prema slijedećoj formuli [, ili njegova farmaceutski prihvatljiva sol, ili hidrat spoja ili njegova sol: t
K2O and Na2O in a total amount of 1 to 6 wt%. 
K20 i Na20 u ukupnoj količini od 1 do 6 tež.%.
The device according to the preceding claims, characterized in that said tube (11) has a cross-section that comprises three lobes (13, 14, 15) arranged substantially at 120 sexagesimal degrees with respect to each other. 
Uređaj u skladu s prethodnim patentnim zahtjevima, naznačen time, da svaki od navedenih dijelova cijevi (11a, 11b, 11c, 11d) ima poprečni presjek koji se sastoji od tri režnja (13,14,15) međusobno raspoređena uglavnom na 120 šezdesetih stupnjeva.
is a candidate to receive treatment with an immunomodulator and enhanced monitoring for adverse symptoms upon treatment with the immunomodulator, optionally wherein the adverse symptoms indicate the development of PML. 
(ili) je kandidat da primi liječenje imunomodulatorom i pojačani nadzor na nepoželjne simptome prilikom liječenja imunomodulatorom, izborno kada nepoželjni simptomi ukazuju na razvoj PML.
A product comprising (a) a B2 agonist and (b) an antagonist of M3 muscarinic receptors as defined in 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease which responds to M3 antagonism. 
Proizvod koji sadrži (a) kortikosteroid kako je definiran u bilo kojem od patentnih zahtjeva 113 do 71 (b) antagonist M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2, naznačen time, da je to proizvod u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju bolesnika koji su oboljeli ili bi mogli oboljeti od respiratorne bolesti kako je definirana u patentnom zahtjevu 11 ili 12.
or a salt of such a compound. 
HR P20110825 T1 ili sol takvoga spoja.
The compound of formula I can be prepared by using suitable protecting groups to block the 3′ and 5′ hydroxyl functions followed by acylation of the N4-amino group. 
Spoj formule I može se dobiti uz upotrebu pogodnih zaštitnih skupina koje blokiraju 3'- i 5'-hidroksilne funkcionalne skupine, uz naknadno aciliranje N*-amino skupine.
wherein a second fragment of said at least two fragments comprises at least 10 consecutive amino acid residues of amino acid residues 205 to 225 of PCSK9 (SEQ ID NO: 9). The immunogen of claim 1, 
Cjepivo prema zahtjevu 1, naznačeno time, da su najmanje dva fragmenta odabrana iz skupine sastavljene od peptida koji imaju aminokiselinsku sekvencu SIPWNLERITPPR (SEQ ID NO:2), PEEDGTRFHRQASK (SEQ ID NO:3),